Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: A prospective study of 1,962 cases

Journal of Urology

Volumn 188, Issue 5, 2012, Pages 1726-1731

  Crawford, E David ^a   Rove, Kyle O ^a   Trabulsi, Edouard J ^b   Qian, Junqi ^c   Drewnowska, Krystyna P ^d   Kaminetsky, Jed C ^g   Huisman, Thomas K ^h   Bilowus, Mark L ^e   Freedman, Sheldon J ⁱ   Glover Jr , W Lloyd ^f   Bostwick, David G ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d BOSTWICK LABORATORIES   (United States)

^e Bilowus Medical   (United States)

^f Fairfax Urology Center   (United States)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Chiaramonte Huisman and Zorn Urology   (United States)

ⁱ NONE

Author keywords

biological markers; biopsy; prostate cancer antigen 3, human; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ATYPICAL SMALL ACINAR PROLIFERATION; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER GRADING; COMMUNITY CARE; DIGITAL RECTAL EXAMINATION; DISEASE SEVERITY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SENSITIVITY AND SPECIFICITY; TRANSRECTAL PROSTATE NEEDLE BIOPSY; TUMOR BIOPSY; TUMOR GENE; UNITED STATES; URINALYSIS;

ANTIGENS, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84867396410     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.07.023     Document Type: Article

References (28)

1. M. Wang, L. Valenzuela, G. Murphy Purification of a human prostate specific antigen Invest Urol 12 1979 159
2. M. Kuriyama, M. Wang, C. Lee Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens J Natl Cancer Inst 68 1982 99
3. W.H. Cooner, B.R. Mosley, C.L. Rutherford Jr Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen J Urol 143 1990 1146
4. D.U. Ekwueme, L.A. Stroud, Y. Chen Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies Prev Chronic Dis 4 2007 A100
5. E.D. Crawford, L. Black, M. Eaddy A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer Prostate Cancer Prostatic Dis 13 2010 162
6. G. Steineck, F. Helgesen, J. Adolfsson Quality of life after radical prostatectomy or watchful waiting N Engl J Med 347 2002 790
7. M. Litwin, J. Gore, L. Kwan Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer Cancer 109 2007 2239
8. I.M. Thompson, D. Ankerst, C. Chi Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower JAMA 294 2005 66
9. I.M. Thompson, P. Goodman, C. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215
10. J. Groskopf, S.M. Aubin, I.L. Deras APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer Clin Chem 52 2006 1089
11. J.R. Day, M. Jost, M.A. Reynolds PCA3: from basic molecular science to the clinical lab Cancer Lett 301 2011 1
12. M.J. Bussemakers, A. van Bokhoven, G.W. Verhaegh DD3: a new prostate-specific gene, highly overexpressed in prostate cancer Cancer Res 59 1999 5975
13. J.B. de Kok, G.W. Verhaegh, R.W. Roelofs DD3(PCA3), a very sensitive and specific marker to detect prostate tumors Cancer Res 62 2002 2695
14. D. Hessels, J.M. Klein Gunnewiek, I. van Oort DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer Eur Urol 44 2003 8
15. I.L. Deras, S.M. Aubin, A. Blase PCA3: a molecular urine assay for predicting prostate biopsy outcome J Urol 179 2008 1587
16. L.S. Marks, D.G. Bostwick Prostate cancer specificity of PCA3 gene testing: examples from clinical practice Rev Urol 10 2008 175
17. M. Auprich, A. Haese, J. Walz External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome Eur Urol 58 2010 727
18. J.S. Jones Management of rising prostate-specific antigen following a negative biopsy Curr Opin Urol 20 2010 198
19. P.C. Albertsen The unintended burden of increased prostate cancer detection associated with prostate cancer screening and diagnosis Urology 75 2010 399
20. M.F. McNaughton-Collins, M.J. Barry One man at a time-resolving the PSA controversy N Engl J Med 365 2011 1951
21. A. Jemal, R. Siegel, J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277
22. M.J. Roobol, F.H. Schröder, P. van Leeuwen Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test Eur Urol 58 2010 475
23. A. de la Taille, J. Irani, M. Graefen Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions J Urol 185 2011 2119
24. F.K. Chun, A. de la Taille, H. van Poppel Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram Eur Urol 56 2009 659
25. J. Morote, M. Rigau, M. Garcia Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia World J Urol 28 2010 677
26. J. Rabets, J. Jones, A. Patel Prostate cancer detection with office based saturation biopsy in a repeat biopsy population J Urol 172 2004 94
27. N.B. Delongchamps, G. de la Roza, R. Jones Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer BJU Int 103 2009 49
28. G.L. Andriole Pathology: the lottery of conventional prostate biopsy Nat Rev Urol 6 2009 188